Conceptus(R) Announces 10-Year Commercial Data for Essure(R) at 40th AAGL Global Congress of Minimally Invasive Gynecology
November 08 2011 - 9:00AM
Conceptus, Inc. (Nasdaq:CPTS), developer of the
Essure® procedure, the most effective non-surgical permanent birth
control method available*, today released a new data report on
Essure's 10-year commercial success at the 40th AAGL Global
Congress of Minimally Invasive Gynecology in Hollywood, Florida,
November 7-10, 2011.
This 10-year global study explores the commercial use of Essure
by approximately 500,000 women. The new data tracks closely with
Essure's clinical effectiveness rate of 99.8% based on four years
of follow-up with zero pregnancies reported in clinical
trials.
"As the pioneer and market leader of hysteroscopic
sterilization, we are pleased to be celebrating this milestone
achievement for the Essure procedure at AAGL this year," said Mark
Sieczkarek, president and chief executive officer of
Conceptus. "Besides being the most effective form of permanent
birth control, Essure is also the leading office-based method of
female sterilization and offers patients a minimally-invasive
procedure that takes less than 10 minutes with no incisions, no
hormones and a short recovery period."
"Most patients have heard about tubal ligation or
vasectomy. However, now that Essure has a decade of
successfully proven commercial experience, it is time that more
OB/GYNs and other healthcare professionals start recommending this
safer, more convenient alternative to appropriate patients," said
Barbara Levy, M.D., medical director for Conceptus.
The AAGL Global Congress will feature more than 20
ground-breaking scientific communications on the Essure system from
presenters around the world. Several of the presentations will
favorably compare Essure to other forms of sterilization including
laparoscopic tubal ligation, vasectomy, and a competitive
hysteroscopic sterilization procedure. Among the presentations
are:
- Reported pregnancies after Essure® Hysteroscopic Sterilization:
A Retrospective Analysis of Pregnancy Reports Worldwide: 2001-2010;
Levy BS, Munro MG, Veersema S, Vleugels M. Women's Health,
Franciscan Health Systems, Federal Way, Washington; Department of
Obstetrics & Gynecology, UCLA David Giffen School of Medicine,
Los Angeles, CA; Department of Obstetrics & Gynecology, St.
Antonius Hospital, Nieuwegein, Netherlands; Department of
Obstetrics & Gynecology, Riverland Hospital Tiel, Tiel,
Netherlands
- A Comparative Study between Hysteroscopic (Essure) Versus
Laparoscopic Sterilization: Patient Satisfaction; Perez C, Lopez G,
Guillen C, Alvarez C, Jimenez JS, Munoz JL, Lorenzo E.
Department of Obstetrics & Gynecology, Madrid, Spain
- Essure Versus Vasectomy: An analysis of Success, Complications,
Pain, and Pregnancy; Smith KS, Gephart LF, Cooper J, Obstetrics
& Gynecology, Howard University Hospital, Washington, DC
- Hysteroscopic Placement of the Essure Device in the
Office-Setting; Levie M, Chudnoff S, Palmer S, To J. Montefiore
Medical Center, Bronx, NY
- Impact of Experience on Essure Placement Rates; Levie M,
Chudnoff S. Obstetrics & Gynecology and Women's Health,
Montefiore Medical Center/Albert Einstein College of Medicine,
Bronx, NY
As a long-standing contributor to AAGL, Conceptus will be an
active participant in several conference activities that focus on
the continuing education of residents and fellows. For
example, the Company will participate in an office-based CME
post-graduate course. At the Conceptus exhibitor booth,
company representatives will celebrate the new 10-year commercial
data results with an historical timeline of key Essure milestones,
as well as provide visitors an opportunity to train on the
Company's state-of-the-art EssureSim™ simulator that replicates the
Essure procedure. The booth will also feature details on the
Essurance™ Promise Program (Patient Reliance Warranty), the Essure
FlexPay™ Plan, and Patient Education Systems digital program that
facilitates patient awareness and education about office-based
gynecological procedures.
"This year's AAGL meeting marks the turning point for Essure
after a decade of clinical excellence. We are positioned to
expand awareness about Essure to both women who are done having
children and the physicians who treat them," said
Sieczkarek. "We share the vision with the members of AAGL to
provide optimal patient care through minimally-invasive gynecology,
and thank them for advancing Essure as a safe and effective
office-based method of permanent birth control."
About the Essure® Procedure
The Essure procedure, FDA approved since 2002, is the first
permanent birth control method that can be performed in the comfort
of a physician's office in less than 10 minutes (average
hysteroscopic time) without hormones, cutting, burning or the risks
associated with general anesthesia or tubal ligation. Soft,
flexible inserts are placed in a woman's fallopian tubes through
the cervix without incisions. Over the next three months, the body
forms a natural barrier around and through the inserts to prevent
sperm from reaching the egg. Three months after the Essure
procedure, a doctor is able to perform an Essure Confirmation Test
to confirm that the inserts are properly placed and that the
fallopian tubes are fully blocked, allowing the patient to rely
upon Essure for permanent birth control.
The Essure procedure is covered by most insurance plans, and
when it is performed in a doctor's office the cost to the patient
may be as low as a simple co-pay. Essure has been proven and
trusted by physicians since 2002, with more than 570,000 women
worldwide having undergone the Essure procedure.
About Conceptus, Inc.
Conceptus, Inc. is a leader in the design, development and
marketing of innovative solutions in women's healthcare. The
Company manufactures and markets the Essure procedure. The
Essure procedure is available in the United States, Europe,
Australia, New Zealand, Canada, Mexico, Central and South America
and the Middle East. The Company also promotes the GYNECARE
THERMACHOICE® Uterine Balloon Therapy System by ETHICON™ Women's
Health & Urology, a division of Ethicon, Inc., in U.S. OB/GYN
physician offices.
Please visit www.essure.com for more information on the Essure
procedure. Patients may call the Essure Information Center at
1-877-ESSURE-1 with questions or to find a physician in their
area.
© 2011 Conceptus, Inc.—All rights reserved. Conceptus and Essure
are trademarks or registered trademarks of Conceptus, Inc.
*Based on 4 years of clinical data
CC-2951 7NOV11F
CONTACT: Investor Relations and Public Relations Contact:
Cindy Klimstra
(650) 962-4032
cindy_klimstra@conceptus.com
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jul 2023 to Jul 2024